Trials / Terminated
TerminatedNCT03320265
Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a
Double-blind, Randomised, Placebo-controlled, Multicentre, Phase IIa Study to Investigate the Effect of PC-mAb on Arterial Inflammation in Subjects With Elevated Lipoprotein a
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Athera Biotechnologies AB · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Inflammation and abnormal amount of lipids in the blood are key factors for the development and progression of atherosclerosis (thickening of the artery wall) and cardiovascular disease. Lipoprotein (a) is a pro-inflammatory plasma lipoprotein that is believed to be a risk factor for cardiovascular diseases. Vascular inflammation generates a range of effects, including endothelial dysfunction and migration of white blood cells into the vessel wall, which results in increased risk of cardiovascular events. This study is designed to assess the effects of multiple monthly intravenous infusions with the fully human antibody called PC-mAb, in subjects with elevated lipoprotein (a).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PC-mAb | Monthly treatment for 3 months (4 administrations) |
| DRUG | Placebo | Monthly treatment for 3 months (4 administrations) |
Timeline
- Start date
- 2017-10-11
- Primary completion
- 2018-03-19
- Completion
- 2018-07-03
- First posted
- 2017-10-25
- Last updated
- 2018-07-06
Locations
2 sites across 2 countries: Netherlands, Sweden
Source: ClinicalTrials.gov record NCT03320265. Inclusion in this directory is not an endorsement.